Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cited by (1,008)

Items 101–200 of 1,008

1. Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
   Crawford, Katharine H D, Dingens, Adam S, Eguia, Rachel, Wolf, Caitlin R, Wilcox, Naomi, Logue, Jennifer K, Shuey, Kiel, Casto, Amanda M, Fiala, Brooke, Wrenn, Samuel et al. · 2021 · The Journal of Infectious Diseases
2. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
   Cheol-Min Kim, Dong-Kyun Ryu, Jihun Lee, Young‐Il Kim, Ji Min Seo, Yeon‐Gil Kim, Jae-Hee Jeong, Minsoo Kim, Jong-In Kim, Pankyeom Kim et al. · 2021 · Nature Communications
3. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
   Ioannis P. Trougakos, Kimon S. Stamatelopoulos, Evangelos Terpos, Ourania Tsitsilonis, Evmorfia Aivalioti, Dimitrios N. Paraskevis, Efstathios Kastritis, George N. Pavlakis, Meletios Athanasios Dimopoulos · 2021 · Journal of Biomedical Science
4. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
   Frauke Muecksch, Yiska Weisblum, C. Barnes, Fabian Schmidt, Dennis J. Schaefer-Babajew, Zi-Jun Wang, Julio C. C. Lorenzi, A. Flyak, A. T. DeLaitsch, Kathryn E. Huey-Tubman et al. · 2021 · Immunity
5. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
   Zhou, Daming, Duyvesteyn, Helen M. E., Chen, Cheng-Pin, Huang, Chung-Guei, Chen, Ting-Hua, Shih, Shin-Ru, Lin, Yi-Chun, Cheng, Chien-Yu, Cheng, Shu-Hsing, Huang, Yhu-Chering et al. · 2020 · Nature Structural & Molecular Biology
6. The immune system and COVID-19: Friend or foe?
   Fereshteh Yazdanpanah, Michael Richard Hamblin, Nima Rezaei · 2020 · Life Sciences
7. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
   Cherian, Sarah, Potdar, Varsha, Jadhav, Santosh, Yadav, Pragya, Gupta, Nivedita, Das, Mousmi, Rakshit, Partha, Singh, Sujeet, Abraham, Priya, Panda, Samiran et al. · 2021
8. Monoclonal antibody therapies against SARS-CoV-2
   Daniele Focosi, Scott A. McConnell, Arturo Casadevall, Emiliano Cappello, Giulia Valdiserra, Marco Tuccori · 2022 · The Lancet Infectious Diseases
9. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
   William N. Voss, Yixuan Jacob Hou, Nicole V. Johnson, George Delidakis, Jin Eyun Kim, Kamyab Javanmardi, Andrew P. Horton, Foteini Bartzoka, Chelsea Paresi, Yuri Tanno et al. · 2021 · Science
10. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
    Mengzhen Dong, Jie Zhang, Xuefeng Ma, Jie Tan, Lizhen Chen, Shousheng Liu, Yongning Xin, Likun Zhuang · 2020 · Biomedicine & Pharmacotherapy
11. The germinal centre B cell response to SARS-CoV-2
    Brian J. Laidlaw, Ali H. Ellebedy · 2021 · Nature reviews. Immunology
12. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
    Saunders, Kevin O., Lee, Esther, Parks, Robert, Martinez, David R., Li, Dapeng, Chen, Haiyan, Edwards, Robert J., Gobeil, Sophie, Barr, Maggie, Mansouri, Katayoun et al. · 2021 · Nature
13. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
    Shuo Du, Y. Cao, Qin-Yu Zhu, Pin Yu, Fei-Fei Qi, Guopeng Wang, Xiaoxia Du, L. Bao, Wei Deng, Hua Zhu et al. · 2020 · Cell
14. Humoral Responses and Serological Assays in SARS-CoV-2 Infections
    Yannick Galipeau, Matthew Greig, Chaojie Liu, Matt Driedger, Marc‐André Langlois · 2020 · Frontiers in Immunology
15. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
    Wang, Ruoke, Zhang, Qi, Ge, Jiwan, Ren, Wenlin, Zhang, Rui, Lan, Jun, Ju, Bin, Su, Bin, Yu, Fengting, Chen, Peng et al. · 2021 · Immunity
16. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
    Xiangyu Chen, Zhiwei Pan, Shuai Yue, Fei Yu, Junsong Zhang, Yang Yang, Ren Li, Bingfeng Liu, Xiaofan Yang, Leiqiong Gao et al. · 2020 · Signal Transduction and Targeted Therapy
17. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
    Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, Pao-Yin Chiang, Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, Tzung-Yang Hsieh, Han‐Chung Wu · 2022 · Journal of Biomedical Science
18. Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2
    Sandra C. A. Nielsen, Fan Yang, Katherine Jackson, Ramona A. Hoh, Katharina Röltgen, Grace H. Jean, Bryan Stevens, Ji-Yeun Lee, Arjun Rustagi, Angela J. Rogers et al. · 2020 · Cell Host & Microbe
19. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
    Li-Qiang Feng, Qian Wang, Shan Chao, Chenchen Yang, Ying Feng, Jia Wu, Xiaolin Liu, Yiwu Zhou, Ren-Di Jiang, Peiyu Hu et al. · 2020 · Nature Communications
20. Aptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection
    Miao Sun, Siwen Liu, Xinyu Wei, Shuang Wan, Mengjiao Huang, Ting Song, Yao Wei W Lu, Xiaonan Weng, Lin Zhu, Honglin Chen et al. · 2021 · Angewandte Chemie International Edition
21. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
    Maria Pia Sormani, Matilde Inglese, Irene Schiavetti, Luca Carmisciano, Alice Laroni, Caterina Lapucci, Giorgio Da Rin, Carlo Serrati, Ilaria Gandoglia, Tiziana Tassinari et al. · 2021 · EBioMedicine
22. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
    Yunlong Cao, Jing Wang, Fanchong Jian, Tianhe Xiao, Weiliang Song, Ayijiang Yisimayi, Weijin Huang, Qianqian Li, Peng Wang, Ran An et al. · 2021 · Nature
23. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
    Fang Wang, Shujia Huang, Rongsui Gao, Yuwen Zhou, Changxiang Lai, Zhichao Li, Wenjie Xian, Xiaobo Qian, Zhiyu Li, Yu‐Shan Huang et al. · 2020 · Cell Discovery
24. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
    Alsoussi, Wafaa B, Turner, Jackson S, Case, James B, Zhao, Haiyan, Schmitz, Aaron J, Zhou, Julian Q, Chen, Rita E, Lei, Tingting, Rizk, Amena A, McIntire, Katherine M et al. · 2020 · The Journal of Immunology
25. Immunological imprinting of the antibody response in COVID-19 patients
    Aydillo, Teresa, Rombauts, Alexander, Stadlbauer, Daniel, Aslam, Sadaf, Abelenda-Alonso, Gabriela, Escalera, Alba, Amanat, Fatima, Jiang, Kaijun, Krammer, Florian, Carratala, Jordi et al. · 2021 · Nature Communications
26. COVID-19 Antibody Tests and Their Limitations
    Guoqiang Liu, James F. Rusling · 2021 · ACS Sensors
27. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination
    Ariane Sternberg, Cord Naujokat · 2020 · Life Sciences
28. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19
    Can Liu, Andrew J. Martins, William W. Lau, Nicholas Rachmaninoff, Jinguo Chen, Luisa Imberti, Darius Mostaghimi, Danielle L. Fink, Peter D. Burbelo, Kerry Dobbs et al. · 2021 · Cell
29. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
    Hejun Liu, Nicholas C. Wu, M. Yuan, S. Bangaru, J. Torres, T. Caniels, J. van Schooten, Xue-Yong Zhu, C. D. Lee, P. Brouwer et al. · 2020 · Immunity
30. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses
    A. Bonifacius, Sabine Tischer-Zimmermann, A. Dragon, Daniel Gussarow, Alexander J. Vogel, Ulrike Krettek, Nina Gödecke, Mustafa Yilmaz, Anke R. M. Kraft, M. Hoeper et al. · 2021 · Immunity
31. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles
    Maolin Lu, Pradeep Devappa Uchil, Wenwei Li, Desheng Zheng, Daniel S. Terry, Jason Gorman, Wei Shi, Baoshan Zhang, Tongqing Zhou, Shilei Ding et al. · 2020 · Cell Host & Microbe
32. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
    Jérémie Prévost, Romain Gasser, Guillaume Beaudoin-Bussières, Jonathan Richard, Ralf Duerr, Annemarie Laumaea, Sai Priya Anand, Guillaume Goyette, Mehdi Benlarbi, Shilei Ding et al. · 2020 · Cell Reports Medicine
33. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
    Pan-Pan Zhou, M. Yuan, G. Song, N. Beutler, N. Shaabani, De-Li Huang, Wan-ting He, Xue-Yong Zhu, Sean Callaghan, Peter Yong et al. · 2022 · Science Translational Medicine
34. Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be
    Giuseppina Mariano, Rebecca J. Farthing, Shamar L. M. Lale-Farjat, Julien R. C. Bergeron · 2020 · Frontiers in Molecular Biosciences
35. A novel cell culture system modeling the SARS-CoV-2 life cycle
    Xiaohui Ju, Yunkai Zhu, Yuyan Wang, Jingrui Li, Jiaxing Zhang, Mingli Gong, Wenlin Ren, Sai Li, Jin Zhong, Linqi Zhang et al. · 2021 · PLoS Pathogens
36. Enhanced binding of the N501Y‐mutated SARS‐CoV‐2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations
    Binquan Luan, Haoran Wang, Tien Huynh · 2021 · FEBS Letters
37. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
    Lamiaa El-Shennawy, Andrew D. Hoffmann, Nurmaa K. Dashzeveg, K. McAndrews, P. Mehl, Daphne Cornish, Zihao Yu, V. Tokars, V. Nicolaescu, A. Tomatsidou et al. · 2022 · Nature Communications
38. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
    Meng Yuan, Hejun Liu, Nicholas C. Wu, Ian A. Wilson · 2020 · Biochemical and Biophysical Research Communications
39. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
    Alexander C. Dowell, Megan Butler, Elizabeth Jinks, Gokhan Tut, Tara Lancaster, Panagiota Sylla, Jusnara Begum, Rachel K. Bruton, Hayden Pearce, Kriti Verma et al. · 2021 · Nature Immunology
40. The humoral response and antibodies against SARS-CoV-2 infection
    Hai Qi, Bo Liu, Xin-Quan Wang, Lin-Qi Zhang · 2022 · Nature Immunology
41. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
    Wesley H. Self, Uriel Sandkovsky, Cavan S. Reilly, David M. Vock, Robert L. Gottlieb, Michael Mack, Kevin Golden, Emma Dishner, Andrew Vekstein, Emily R. Ko et al. · 2021 · The Lancet Infectious Diseases
42. The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET
    Chuang Liu, Luiza Mendonça, Yang Yang, Yuanzhu Gao, Chenguang Shen, Jiwei Liu, Tao Ni, Bin Ju, Congcong Liu, Xian Tang et al. · 2020 · Structure
43. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
    Yuezhou Chen, Adam Zuiani, Stephanie Fischinger, Jyotsna Mullur, Caroline G. Atyeo, Meghan E. Travers, Felipe Lelis, Krista M. Pullen, Hannah Martin, Pei Tong et al. · 2020 · Cell
44. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
    Ku, Zhiqiang, Xie, Xuping, Davidson, Edgar, Ye, Xiaohua, Su, Hang, Menachery, Vineet D., Li, Yize, Yuan, Zihao, Zhang, Xianwen, Muruato, Antonio E. et al. · 2021 · Nature Communications
45. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
    Cheng Li, Wuqiang Zhan, Zhenlin Yang, Chao Tu, Gaowei Hu, Xiang Zhang, Wenping Song, Shujuan Du, Yuanfei Zhu, Keke Huang et al. · 2022 · Cell
46. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
    Yifan Wang, Caixuan Liu, Chao Zhang, Yanxing Wang, Hong Qin, Shiqi Xu, Zuyang Li, Yong Ping Yang, Zhong Wei Huang, Yao Cong · 2022 · Nature Communications
47. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
    Jingwen Ai, Xun Wang, Xinyi He, Xiaoyu Zhao, Yi Zhang, Yuchao Jiang, Minghui Li, Yuchen Cui, Yanjia Chen, Rui Qiao et al. · 2022 · Cell Host & Microbe
48. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
    A. Kuzmina, Y. Khalaila, O. Voloshin, A. Keren-Naus, Liora Boehm-Cohen, Y. Raviv, Y. Shemer-Avni, Elli Rosenberg, R. Taube · 2021 · Cell Host and Microbe
49. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
    Nicholas K. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, Venkata Viswanadh Edara, Andrew B. Stuart, Junli Feng, Mehul S. Suthar, Andrew T. McGuire, Leonidas Stamatatos, Marie Pancera · 2020 · Nature Communications
50. Monoclonal antibody as a potential anti-COVID-19
    Leila Jahanshahlu, Nima Rezaei · 2020 · Biomedicine & Pharmacotherapy
51. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
    Monir Ejemel, Qi Li, Shurong Hou, Zachary A. Schiller, Julia A. Tree, Aaron Wallace, Alla Amcheslavsky, Neşe Kurt Yılmaz, Karen R. Buttigieg, Michael J. Elmore et al. · 2020 · Nature Communications
52. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
    Sham Nambulli, Yufei Xiang, N. L. Tilston-Lunel, L. Rennick, Z. Sang, W. Klimstra, D. Reed, N. Crossland, Yi Shi, W. P. Duprex · 2021 · Science Advances
53. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
    Alexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, Shang Yu Gong, Romain Gasser, Guillaume Beaudoin-Bussières, Nathalie Brassard, Annemarie Laumaea, Dani Vézina, Jérémie Prévost et al. · 2021 · Cell Host & Microbe
54. Comparison of the immunogenicity of <scp>BNT162b2</scp> and <scp>CoronaVac COVID</scp> ‐19 vaccines in Hong Kong
    Mok, Chris Ka Pun, Cohen, Carolyn A., Cheng, Samuel M. S., Chen, Chunke, Kwok, Kin‐On, Yiu, Karen, Chan, Tat‐On, Bull, Maireid, Ling, Kwun Cheung, Dai, Zixi et al. · 2022 · Respirology
55. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
    Yang Li, Ming‐liang Ma, Qing Lei, Feng Wang, Wei Hong, Dan‐yun Lai, Hongyan Hou, Zhaowei Xu, Bo Zhang, Hong Chen et al. · 2021 · Cell Reports
56. Cell entry by SARS-CoV-2
    Ruchao Peng, Lian-Ao Wu, Qingling Wang, Jianxun Qi, George F. Gao · 2021 · Trends in Biochemical Sciences
57. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
    C. Chakraborty, A. R. Sharma, M. Bhattacharya, G. Agoramoorthy, Sang-Soo Lee · 2021 · Frontiers in Pharmacology
58. Antibodies and Vaccines Target RBD of SARS-CoV-2
    L. Min, Qiu Sun · 2021 · Frontiers in Molecular Biosciences
59. Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization
    Shan, Sisi, Luo, Shitong, Yang, Ziqing, Hong, Junxian, Su, Yufeng, Ding, Fan, Fu, Lili, Li, Chenyu, Chen, Peng, Ma, Jianzhu et al. · 2022 · Proceedings of the National Academy of Sciences
60. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2
    Lu Qiao, Jia Liu, Shuai Zhao, María Florencia Gómez Castro, Maudry Laurent-Rolle, Jianbo Dong, Xiaojuan Ran, Payal Damani‐Yokota, Hongzhen Tang, Triantafyllia R. Karakousi et al. · 2021 · Immunity
61. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
    Nicholas C. Wu, Meng Yuan, Hejun Liu, Chang-Chun David Lee, Xueyong Zhu, Sandhya Bangaru, Jonathan L. Torres, Tom G. Caniels, Philip J. M. Brouwer, Marit J. van Gils et al. · 2020 · Cell Reports
62. COVID-19: Progress in diagnostics, therapy and vaccination
    Xue Liu, Chao Liu, Gang Liu, Wenxin Luo, Ningshao Xia · 2020 · Theranostics
63. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
    Tatjana Bilich, Annika Nelde, Jonas S. Heitmann, Yacine Maringer, Malte Roerden, Jens Bauer, Jonas Rieth, Marcel Wacker, Andreas Peter, Sebastian Hörber et al. · 2021 · Science Translational Medicine
64. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
    Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, Jhih‐Liang Huang, Fu‐Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, Joyce Pei‐Yi Yuan et al. · 2022 · Journal of Biomedical Science
65. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
    Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, Logan T. Neel, Tharanath Shankar, Shriya Patel, Payton Lowery, Forrest Smith, Muralikrishnan Dhanasekaran, Timothy Moore · 2021 · Vaccines
66. SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
    Annachiara Rosa, V. E. Pye, C. Graham, L. Muir, J. Seow, K. Ng, N. Cook, C. Rees-Spear, Eleanor Parker, M. S. dos Santos et al. · 2021 · SciAdv
67. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
    J. Huo, H. Mikolajek, A. Le Bas, J. Clark, Parul Sharma, A. Kipar, Joshua Dormon, Chelsea S. Norman, M. Weckener, D. Clare et al. · 2021 · Nature Communications
68. An Update on Molecular Diagnostics for COVID-19
    Khursheed Ul Islam, Jawed Iqbal · 2020 · Frontiers in Cellular and Infection Microbiology
69. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
    J. Ge, Ruoke Wang, B. Ju, Qi Zhang, Jing Sun, Peng Chen, Senyan Zhang, Yuling Tian, S. Shan, Lin Cheng et al. · 2021 · Nature Communications
70. A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism**
    Anton Schmitz, Anna Weber, Mehtap Bayin, Stefan Breuers, Volkmar Fieberg, Michael Famulok, Günter Mayer · 2021 · Angewandte Chemie International Edition
71. Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses
    J. Tas, Ja-Hyun Koo, Ying-Cing Lin, Zhenfei Xie, J. Steichen, A. Jackson, B. Hauser, Xuesong Wang, C. Cottrell, J. Torres et al. · 2022 · Immunity
72. Development of a rapid Focus Reduction Neutralization Test Assay for measuring SARS-CoV-2 neutralizing antibodies
    Abigail Vanderheiden, V. Edara, K. Floyd, Robert C Kauffman, G. Mantus, E. Anderson, N. Rouphael, S. Edupuganti, Pei-Yong Shi, V. Menachery et al. · 2020 · Current Protocols in Immunology
73. Antibody-mediated neutralization of SARS-CoV-2
    Henning Gruell, Kanika Vanshylla, Timm Weber, Christopher O. Barnes, Christoph Kreer, Florian Klein · 2022 · Immunity
74. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
    Tânia F. Custódio, Hrishikesh Das, Daniel J. Sheward, Leo Hanke, Samuel Pažický, Joanna Pieprzyk, Michèle Sorgenfrei, Martin A. Schroer, Andrey Yu. Gruzinov, Cy Michael Jeffries et al. · 2020 · Nature Communications
75. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
    S. Long, R. Olsen, Paul A. Christensen, David W. Bernard, James J. Davis, M. Shukla, M. Nguyen, M. Saavedra, Prasanti Yerramilli, Layne Pruitt et al. · 2020 · mBio
76. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
    Line K. Vibholm, S. Nielsen, M. H. Pahus, Giacomo S. Frattari, R. Olesen, R. Andersen, Ida Monrad, A. Andersen, Michelle M. Thomsen, C. Konrad et al. · 2021 · EBioMedicine
77. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
    P. Pymm, Amy Adair, L. Chan, James P. Cooney, F. Mordant, C. Allison, E. Lopez, E. Haycroft, O, M. Neill et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
78. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
    Damir Bojadzic, Oscar Alcazar, Jinshui Chen, Sung-Ting Chuang, José Manuel Cóndor Capcha, Lina A. Shehadeh, Péter Buchwald · 2021 · ACS Infectious Diseases
79. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
    Natalie Yan‐Lin Pang, Alexander Shao‐Rong Pang, Vincent T. K. Chow, De Yun Wang · 2021 · Military Medical Research
80. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    RECOVERY Collaborative Group, Peter Horby, Marion M. Mafham, Leon Peto, Mark Robin Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan Emberson, Benjamin Prudon et al. · 2021 · medRxiv
81. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
    Lihong Liu, Sho Iketani, Yicheng Guo, Jasper Fuk‐Woo Chan, Maple Wang, Liyuan Liu, Yang Luo, Hin Chu, Yiming Huang, Manoj S. Nair et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
82. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
    Carmen Riggioni, Pasquale Comberiati, Mattia Giovannini, Ioana Octavia Agache, Mübeccel Akdiş, Magna Alves‐Correia, Josep M. Antó, Alessandra Arcolacı, Ahmet Kürşat Azkur, Dilek Azkur et al. · 2020 · Allergy
83. SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment
    Dapeng Li, Gregory D. Sempowski, Kevin O. Saunders, Priyamvada Acharya, Barton F. Haynes · 2021 · Annual Review of Medicine
84. Antibody Responses in COVID-19: A Review
    Mateo Chvatal‐Medina, Yorjagis Andres Mendez Cortina, Pablo Javier Patiño Grajales, Paula A. Velilla, Marı́a Teresa Rugeles · 2021 · Frontiers in Immunology
85. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
    McCallum, Matthew, Marco, Anna De, Lempp, Florian, Tortorici, M. Alejandra, Pinto, Dora, Walls, Alexandra C., Beltramello, Martina, Chen, Alex, Liu, Zhuoming, Zatta, Fabrizia et al. · 2021
86. Antibody Persistence in the Six Months Following SARS-CoV-2 Infection Among Hospital Workers
    Arnaud Grégoire L’Huillier, Benjamin Meyer, Diego O. Andrey, Isabelle Arm‐Vernez, Stéphanie Baggio, Arnaud M. Didierlaurent, Christiane Sigrid Eberhardt, Isabella Eckerle, Carole Grasset Salomon, Angela Huttner et al. · 2020 · Clinical Microbiology and Infection
87. Development of therapeutic antibodies for the treatment of diseases
    Zeng Wang, Guoqing Wang, Huaqing Lu, Hongjian Li, Mei Tang, Aiping Tong · 2022 · Molecular Biomedicine
88. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
    Yunjiao Zhou, Ze-Zhong Liu, Shi-Bo Li, Wei Xu, Qian-Qian Zhang, I. T. Silva, Cheng Li, Yan-Ling Wu, Qing-Ling Jiang, Zhen-Mi Liu et al. · 2021 · Cell Reports
89. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
    Yusuke Higuchi, Tatsuya Suzuki, Takao Arimori, Nariko Ikemura, Emiko Mihara, Yuhei Kirita, Eriko Ohgitani, Osam Mazda, Daisuke Motooka, Shota Nakamura et al. · 2021 · Nature Communications
90. Neutralizing antibodies for the prevention and treatment of COVID-19
    L. Du, Yang Yang, Xiujuan Zhang · 2021 · Cellular & Molecular Immunology
91. Antibody and B cell responses to SARS-CoV-2 infection and vaccination
    Katharina Röltgen, Scott Dexter Boyd · 2021 · Cell Host & Microbe
92. Clinical sensitivity and interpretation of PCR and serological COVID‐19 diagnostics for patients presenting to the hospital
    Miller, Tyler E., Garcia Beltran, Wilfredo F., Bard, Adam Z., Gogakos, Tasos, Anahtar, Melis N., Astudillo, Michael Gerino, Yang, Diane, Thierauf, Julia, Fisch, Adam S., Mahowald, Grace K. et al. · 2020 · The FASEB Journal
93. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants
    Aurélien Sokal, Giovanna Barba Spaeth, Ignacio Fernández, Matteo Broketa, Imane Azzaoui, Andréa de La Selle, Alexis Vandenberghe, Slim Fourati, Anaïs Roeser, Annalisa Meola et al. · 2021 · Immunity
94. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
    Wenwei Li, Yaozong Chen, Jérémie Prévost, Irfan Ullah, Maolin Lu, Shang Yu Gong, Alexandra Tauzin, Romain Gasser, Dani Vézina, Sai Priya Anand et al. · 2021 · Cell Reports
95. Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications
    Yufeng Wei, Rameen Shah · 2020 · Pharmaceuticals
96. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection
    Peter van der Ley, Afshin Zariri, Elly van Riet, Dinja Oosterhoff, Corine P. Kruiswijk · 2021 · Frontiers in Immunology
97. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
    Jéromine Klingler, Svenja Weiß, Vincenza Itri, Xiaomei Liu, Kasopefoluwa Y. Oguntuyo, Christian S. Stevens, Satoshi Ikegame, Chuan-Tien Hung, Gospel M Enyindah-Asonye, Fatima Amanat et al. · 2020 · The Journal of Infectious Diseases
98. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
    Fei Yu, Rong Xiang, Xiaoqian Deng, Lili Wang, Zhengsen Yu, Shijun Tian, Ruiying Liang, Yanbai Li, Tianlei Ying, Shibo Jiang · 2020 · Signal Transduction and Targeted Therapy
99. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
    Cyrielle E. Fougeroux, Louise Goksøyr, Manja Idorn, Vladislav Soroka, Sebenzile K. Myeni, Robert Dagil, Christoph Mikkel Janitzek, Max Søgaard, Kara-Lee Aves, Emma Wenzel Horsted et al. · 2021 · Nature Communications
100. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
     Qi Zhang, B. Ju, J. Ge, J. Chan, Lin Cheng, Ruoke Wang, Wei-Jing Huang, Mengqi Fang, Peng Chen, Bingjie Zhou et al. · 2021 · Nature Communications